Trade Galectin Therapeutics Inc. - GALT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.0270 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Galectin Therapeutics Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.7665 |
Open* | 1.7265 |
1-Year Change* | 2.77% |
Day's Range* | 1.6765 - 1.7765 |
52 wk Range | 1.02-2.47 |
Average Volume (10 days) | 26.52K |
Average Volume (3 months) | 1.20M |
Market Cap | 104.87M |
P/E Ratio | -100.00K |
Shares Outstanding | 59.58M |
Revenue | N/A |
EPS | -0.67 |
Dividend (Yield %) | N/A |
Beta | 1.33 |
Next Earnings Date | Nov 13, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 22, 2023 | 1.7465 | 0.0300 | 1.75% | 1.7165 | 1.7765 | 1.6665 |
Sep 21, 2023 | 1.7665 | 0.0300 | 1.73% | 1.7365 | 1.7765 | 1.6965 |
Sep 20, 2023 | 1.7765 | -0.0800 | -4.31% | 1.8565 | 1.9165 | 1.7465 |
Sep 19, 2023 | 1.9165 | 0.0700 | 3.79% | 1.8465 | 1.9365 | 1.8465 |
Sep 18, 2023 | 1.9365 | 0.1600 | 9.01% | 1.7765 | 1.9565 | 1.7765 |
Sep 15, 2023 | 1.7565 | -0.1400 | -7.38% | 1.8965 | 1.9065 | 1.7365 |
Sep 14, 2023 | 1.9065 | -0.0600 | -3.05% | 1.9665 | 1.9665 | 1.8765 |
Sep 13, 2023 | 1.9065 | 0.0800 | 4.38% | 1.8265 | 1.9365 | 1.7865 |
Sep 12, 2023 | 1.7865 | 0.1400 | 8.50% | 1.6465 | 1.8065 | 1.6465 |
Sep 11, 2023 | 1.6665 | 0.0400 | 2.46% | 1.6265 | 1.6765 | 1.6265 |
Sep 8, 2023 | 1.7160 | 0.0100 | 0.59% | 1.7060 | 1.7360 | 1.7060 |
Sep 7, 2023 | 1.7360 | 0.1000 | 6.11% | 1.6360 | 1.7460 | 1.6360 |
Sep 6, 2023 | 1.6360 | -0.0400 | -2.39% | 1.6760 | 1.6760 | 1.6260 |
Sep 5, 2023 | 1.6960 | -0.0500 | -2.86% | 1.7460 | 1.7560 | 1.6360 |
Sep 1, 2023 | 1.7560 | 0.0800 | 4.77% | 1.6760 | 1.7560 | 1.6560 |
Aug 31, 2023 | 1.7460 | 0.0300 | 1.75% | 1.7160 | 1.7460 | 1.6660 |
Aug 30, 2023 | 1.7160 | 0.0200 | 1.18% | 1.6960 | 1.7560 | 1.6960 |
Aug 29, 2023 | 1.7360 | 0.0500 | 2.97% | 1.6860 | 1.7360 | 1.6560 |
Aug 28, 2023 | 1.6760 | 0.0500 | 3.08% | 1.6260 | 1.6760 | 1.6260 |
Aug 25, 2023 | 1.6260 | 0.0500 | 3.17% | 1.5760 | 1.6560 | 1.5760 |
Galectin Therapeutics Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Monday, November 13, 2023 | ||
Time (UTC) 13:30 | Country US
| Event Q3 2023 Galectin Therapeutics Inc Earnings Release Q3 2023 Galectin Therapeutics Inc Earnings ReleaseForecast -Previous - |
Friday, December 1, 2023 | ||
Time (UTC) 16:00 | Country US
| Event Galectin Therapeutics Inc Annual Shareholders Meeting Galectin Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 38.352 | 30.179 | 23.444 | 13.438 | 13.602 |
Selling/General/Admin. Expenses, Total | 6.615 | 6.361 | 5.468 | 5.971 | 7.131 |
Research & Development | 31.737 | 23.818 | 17.976 | 7.467 | 6.471 |
Operating Income | -38.352 | -30.179 | -23.444 | -13.438 | -13.602 |
Interest Income (Expense), Net Non-Operating | -0.424 | -0.348 | -0.021 | 0.144 | -0.298 |
Net Income Before Taxes | -38.776 | -30.527 | -23.465 | -13.294 | -13.9 |
Net Income After Taxes | -38.776 | -30.527 | -23.465 | -13.294 | -13.9 |
Net Income Before Extra. Items | -38.776 | -30.527 | -23.465 | -13.294 | -13.9 |
Net Income | -38.776 | -30.527 | -23.465 | -13.294 | -13.9 |
Total Adjustments to Net Income | -0.097 | -0.171 | -0.137 | -6.885 | -1.147 |
Income Available to Common Excl. Extra. Items | -38.873 | -30.698 | -23.602 | -20.179 | -15.047 |
Income Available to Common Incl. Extra. Items | -38.873 | -30.698 | -23.602 | -20.179 | -15.047 |
Diluted Net Income | -38.873 | -30.698 | -23.602 | -20.179 | -15.047 |
Diluted Weighted Average Shares | 59.391 | 58.527 | 57.029 | 52.238 | 39.414 |
Diluted EPS Excluding Extraordinary Items | -0.65453 | -0.52451 | -0.41386 | -0.38629 | -0.38177 |
Diluted Normalized EPS | -0.65453 | -0.52451 | -0.41386 | -0.38629 | -0.38177 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 9.003 | 10.342 | 10.633 | 8.122 | 9.662 |
Selling/General/Admin. Expenses, Total | 1.632 | 1.543 | 1.626 | 1.524 | 1.588 |
Research & Development | 7.371 | 8.799 | 9.007 | 6.598 | 8.074 |
Operating Income | -9.003 | -10.342 | -10.633 | -8.122 | -9.662 |
Interest Income (Expense), Net Non-Operating | -0.111 | -1.185 | -0.001 | -0.475 | 0.049 |
Net Income Before Taxes | -9.114 | -11.527 | -10.634 | -8.597 | -9.613 |
Net Income After Taxes | -9.114 | -11.527 | -10.634 | -8.597 | -9.613 |
Net Income Before Extra. Items | -9.114 | -11.527 | -10.634 | -8.597 | -9.613 |
Net Income | -9.114 | -11.527 | -10.634 | -8.597 | -9.613 |
Total Adjustments to Net Income | -0.063 | 0 | -0.065 | 0.016 | -0.064 |
Income Available to Common Excl. Extra. Items | -9.177 | -11.527 | -10.699 | -8.581 | -9.677 |
Income Available to Common Incl. Extra. Items | -9.177 | -11.527 | -10.699 | -8.581 | -9.677 |
Diluted Net Income | -9.177 | -11.527 | -10.699 | -8.581 | -9.677 |
Diluted Weighted Average Shares | 59.582 | 59.48 | 59.424 | 59.396 | 59.389 |
Diluted EPS Excluding Extraordinary Items | -0.15402 | -0.1938 | -0.18005 | -0.14447 | -0.16294 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.15402 | -0.1938 | -0.18005 | -0.14447 | -0.16294 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 20.552 | 41.82 | 29.465 | 48.209 | 8.832 |
Cash and Short Term Investments | 18.592 | 39.648 | 27.142 | 47.48 | 8.253 |
Cash & Equivalents | 18.592 | 39.648 | 27.142 | 47.48 | 8.253 |
Prepaid Expenses | 1.96 | 2.172 | 2.323 | 0.729 | 0.579 |
Total Assets | 21.285 | 41.827 | 29.6 | 48.467 | 9.006 |
Property/Plant/Equipment, Total - Net | 0.086 | 0.007 | 0.048 | 0.084 | 0 |
Property/Plant/Equipment, Total - Gross | 0.081 | 0.122 | 0.158 | 0.074 | |
Accumulated Depreciation, Total | -0.074 | -0.074 | -0.074 | -0.074 | |
Intangibles, Net | 0 | ||||
Total Current Liabilities | 13.012 | 9.033 | 5.399 | 2.82 | 2.108 |
Accounts Payable | 3.89 | 1.805 | 1.292 | 1.661 | 0.297 |
Accrued Expenses | 9.058 | 7.163 | 4.042 | 1.093 | 1.512 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.064 | 0.065 | 0.065 | 0.066 | 0.299 |
Total Liabilities | 53.479 | 39.211 | 5.407 | 2.872 | 2.108 |
Total Long Term Debt | 39.828 | 29.048 | 0 | 0 | 0 |
Total Equity | -32.194 | 2.616 | 24.193 | 45.595 | 6.898 |
Redeemable Preferred Stock | 2.233 | 2.25 | 2.25 | 2.26 | 2.26 |
Preferred Stock - Non Redeemable, Net | 6.682 | ||||
Common Stock | 0.059 | 0.059 | 0.056 | 0.056 | 0.041 |
Additional Paid-In Capital | 275.081 | 271.001 | 261.883 | 259.673 | 194.13 |
Retained Earnings (Accumulated Deficit) | -309.567 | -270.694 | -239.996 | -216.394 | -196.215 |
Total Liabilities & Shareholders’ Equity | 21.285 | 41.827 | 29.6 | 48.467 | 9.006 |
Total Common Shares Outstanding | 59.426 | 59.3413 | 57.0771 | 56.8946 | 41.1909 |
Total Preferred Shares Outstanding | 1.26018 | 1.30268 | 1.30268 | 1.32768 | 6.83568 |
Other Long Term Assets, Total | 0.647 | 0.087 | 0.174 | 0.174 | |
Other Liabilities, Total | 0.639 | 1.13 | 0.008 | 0.052 | |
Long Term Debt | 39.828 | 29.048 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 19.552 | 20.552 | 17.121 | 25.785 | 33.507 |
Cash and Short Term Investments | 17.799 | 18.592 | 15.831 | 24.178 | 31.606 |
Cash & Equivalents | 17.799 | 18.592 | 15.831 | 24.178 | 31.606 |
Prepaid Expenses | 1.753 | 1.96 | 1.29 | 1.607 | 1.901 |
Total Assets | 20.225 | 21.285 | 17.914 | 25.886 | 33.615 |
Property/Plant/Equipment, Total - Net | 0.078 | 0.086 | 0.093 | 0.101 | 0.108 |
Other Long Term Assets, Total | 0.595 | 0.647 | 0.7 | ||
Total Current Liabilities | 11.533 | 13.012 | 9.588 | 10.892 | 9.535 |
Accounts Payable | 2.553 | 3.89 | 2.352 | 2.964 | 1.906 |
Accrued Expenses | 8.98 | 9.058 | 7.236 | 7.864 | 7.629 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 0.064 | 0 | 0.064 | 0 |
Total Liabilities | 62.871 | 53.479 | 40.249 | 41.109 | 39.808 |
Total Long Term Debt | 49.941 | 39.828 | 29.734 | 29.504 | 29.275 |
Other Liabilities, Total | 1.397 | 0.639 | 0.927 | 0.713 | 0.998 |
Total Equity | -42.646 | -32.194 | -22.335 | -15.223 | -6.193 |
Redeemable Preferred Stock | 2.233 | 2.233 | 2.233 | 2.233 | 2.25 |
Common Stock | 0.059 | 0.059 | 0.059 | 0.059 | 0.059 |
Additional Paid-In Capital | 276.156 | 275.081 | 274.241 | 272.772 | 272.108 |
Retained Earnings (Accumulated Deficit) | -321.094 | -309.567 | -298.868 | -290.287 | -280.61 |
Total Liabilities & Shareholders’ Equity | 20.225 | 21.285 | 17.914 | 25.886 | 33.615 |
Total Common Shares Outstanding | 59.5822 | 59.426 | 59.426 | 59.3958 | 59.3885 |
Total Preferred Shares Outstanding | 1.26018 | 1.26018 | 1.26018 | 1.26018 | 1.30268 |
Long Term Debt | 49.941 | 39.828 | 29.734 | 29.504 | 29.275 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -38.776 | -30.527 | -23.465 | -13.294 | -13.9 |
Cash From Operating Activities | -31.056 | -24.308 | -20.601 | -10.848 | -10.179 |
Cash From Operating Activities | 0 | ||||
Non-Cash Items | 2.752 | 2.468 | 1.922 | 1.805 | 4.793 |
Changes in Working Capital | 4.968 | 3.751 | 0.942 | 0.641 | -1.072 |
Cash From Investing Activities | 0 | 0 | 0 | ||
Capital Expenditures | 0 | ||||
Cash From Financing Activities | 10 | 36.814 | 0.263 | 50.075 | 15.379 |
Issuance (Retirement) of Stock, Net | 0 | 6.814 | 0.263 | 50.469 | 15.379 |
Net Change in Cash | -21.056 | 12.506 | -20.338 | 39.227 | 5.2 |
Total Cash Dividends Paid | 0 | -0.394 | |||
Other Investing Cash Flow Items, Total | 0 | 0 | |||
Issuance (Retirement) of Debt, Net | 10 | 30 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -11.527 | -38.776 | -28.142 | -19.545 | -9.932 |
Cash From Operating Activities | -10.793 | -31.056 | -23.817 | -15.47 | -8.042 |
Non-Cash Items | 1.607 | 2.752 | 2.206 | 1.176 | 0.719 |
Changes in Working Capital | -0.873 | 4.968 | 2.119 | 2.899 | 1.171 |
Cash From Financing Activities | 10 | 10 | 0 | 0 | 0 |
Issuance (Retirement) of Stock, Net | 0 | 0 | 0 | 0 | |
Net Change in Cash | -0.793 | -21.056 | -23.817 | -15.47 | -8.042 |
Issuance (Retirement) of Debt, Net | 10 | 10 | 0 | 0 | |
Cash From Investing Activities | 0 | ||||
Other Investing Cash Flow Items, Total | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Galectin Therapeutics Inc. Company profile
About Galectin Therapeutics Inc
Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 49% to $23.4M. Higher net loss reflects Research and development increase of 58% to $17.7M (expense), Other General and administrative increase of 15% to $3.6M (expense), Stock-based Compensation in SGA increase of 38% to $1.2M (expense).
Equity composition
Common Stock $.001 Par, 03/12, 300M auth., 12,842,850 issd. Insiders own 18.44%. Ser. A Pref. Stock 5M auth., 1,592,500 issd. Redeemable convt. Pref. stock Ser. B-1 900,000 auth., 900,000 issd. Ser. B-2 2.1M auth., 2,100,000 issd. PO 12/13/01, 1,428,572 shares @ $3.50by Atlas Capital Services LLC. 03/12. 1-for-6 Reverse split.
Industry: | Biotechnology & Medical Research (NEC) |
Suite 240
4960 Peachtree Industrial Boulevard
NORCROSS
GEORGIA 30071
US
Income Statement
- Annual
- Quarterly
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com